{"prompt": "['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'V.', 'Approximately 6 mL of blood will be collected by venipuncture for pharmacokinetic (PK), Anti-therapeutic antibody (ATA), and neutralizing antibodies (nAb) testing. The', 'pre-infusion sample will be collected prior to dosing on Day 1 (-3 days window is permitted) and the second sample will be collected within 60 minutes post-infusion. Only', 'one collection will be required at the Non-Treatment Cycle visit and EOT visit. The date and time of each sample collected will be recorded to the nearest minute.', 'W.', 'Archived or fresh tumor material must be submitted to the AbbVie designated central IHC laboratory for determination of DLL3 expression prior to randomization.', 'X.', 'On Day 1 (-3 days window is permitted) of each cycle, the collection will be pre-infusion. A sample will also be collected at the EOT or at the time of disease progression.', 'y. Whole blood sample will be collected for CTC analysis at pre-dose on Cycle 1 Day 1 (-3 days window is permitted) and EOT only at specific sites based on feasibility.', 'z. Pharmacogenetic collection should occur unless precluded by local or national regulations or policies. Pharmacogentic sample collected pre-infusion on Day 1 of Cycle 1.', 'aa.', 'Any pericardial, pleural, and/or ascitic fluid collected as part of routine care (e.g., as part of a therapeutic thoracentesis, pericardiocentesis, or paracentesis) will be procured', 'for', 'testing', 'for any AE starting from C1D1 through 70 days after the last blinded study treatment. Collected fluid must also be tested locally for cytology if disease', 'progression due to appearance/worsening of effusion is suspected.', '126']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix D.', 'Performance Status Scales Conversion', 'ECOG', 'Karnofsky', 'Score', 'Description', 'Percent', 'Description', '0', 'Normal activity. Fully active, able to', '100', 'Normal, no complaints, no evidence', 'carry on all pre-disease performance', 'of disease.', 'without restriction.', '90', 'Able to carry on normal activity;', 'minor signs or symptoms of disease.', '1', 'Symptoms, but ambulatory. Restricted', '80', 'Normal activity with effort; some', 'in physically strenuous activity, but', 'signs or symptoms of disease.', 'ambulatory and able to carry out work of', '70', 'Cares for self, unable to carry on', 'a light or sedentary nature (e.g., light', 'normal activity or to do active work.', 'housework, office work).', '2', 'In bed < 50% of the time. Ambulatory', '60', 'Requires occasional assistance, but is', 'and capable of all self-care, but unable to', 'able to care for most of his/her needs.', 'carry out any work activities. Up and', '50', 'Requires considerable assistance and', 'about more than 50% of waking hours.', 'frequent medical care.', '3', 'In bed > 50% of the time. Capable of', '40', 'Disabled, requires special care and', 'only limited self-care, confined to bed or', 'assistance.', 'chair more than 50% of waking hours.', '30', 'Severely disabled, hospitalization', 'indicated. Death not imminent.', '4', '100% bedridden. Completely disabled.', '20', 'Very sick, hospitalization indicated.', 'Cannot carry on any self-care. Totally', 'Death not imminent.', 'confined to bed or chair.', '10', 'Moribund, fatal processes', 'progressing rapidly.', '5', 'Dead.', '0', 'Dead.', '127']['abbvie', 'Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Appendix E.', 'Calculated Creatinine Clearance Using Modified Cockcroft-Gault', 'Equation', 'MODIFIED COCKCROFT AND GAULT FORMULA', 'For the calculation of estimated creatinine clearance rate (eCCR) using Ideal Body', 'Mass [IBM] instead of Mass.', '(140 - Age) IBM (kg) [0.85 if Female]', 'eCCr', '=', '72', 'Serum Creatinine (mg/dL)', 'Or, if serum creatinine is in mol/L:', '(140 - Age)', 'IBM (kg)', '[1.23 if Male, 1.04 if Female]', 'eCCr', '=', 'Serum Creatinine (umol/L)', 'Ideal Body Mass should be used:', 'IBM (kg) = [(height cm - 154) . 0.9] + (50 if Male, 45.5 if Female)', '128']\n\n###\n\n", "completion": "END"}